One of the major factors driving the growth of the companion diagnostic market is the increasing demand for personalized medicines and awareness about the same among the population. With companies increasing their collaborations for better biomarkers and diagnostics to focus on cost regulations, there have been significant number of oppor tunities for their application in indications other than in cancer, like cardiovascular and neurological. The high rise in capital is the basis for the prosperous future of this market. Companion diagnostics is becoming an indispensable part of personalized medicine and is expected to gain prominence in therapeutics used for the treatment of various diseases. The use of companion diagnostics is taking up a central role as an important treatment decision tool for a number of oncology drugs, and it is also reflected in the way the FDA classifies these assays in relation to risk. In the United States, companion diagnostics assays are classified as IVD class III products, representing a highrisk category, and consequently the highest level of regulatory control.

1. INTRODUCTION

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

5. MARKET SEGMENTATION

6. COMPANY PROFILES AND COMPETITIVE LANDSCAPE

7. MARKET OPPORTUNITIES AND FUTURE TRENDS